Related content

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

By Lynde Charles  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States

By Anis Aslam H.   Bansback Nick   Sizto Sonia   Gupta Shiraz R.   Willian Mary K.   Feldman Steve R.  

Journal of Dermatological Treatment, Vol. 22, Iss. 2, 2011-04 ,pp. : 65-74

Informa Healthcare

Access to resources Recommend Favorite

An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis

By Gupta Rishu   Levin Ethan   Wu Jashin J.   Koo John   Liao Wilson  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 87-89

Informa Healthcare

Access to resources Recommend Favorite

Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis

By Au Shiu-Chung  

Journal of Dermatological Treatment, Vol. 24, Iss. 3, 2013-06 ,pp. : 179-187

Informa Healthcare

Access to resources Recommend Favorite